Acrivon Therapeutics, Inc. Common Stock (ACRV) Form 3 Acrivon Therapeutics / Katharine Peterson ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Peterson Katharine

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MA 02472

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/13/2024

3. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Accounting Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	4,832(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	08/04/2032	Common Stock	56,772	4.07	D
Stock Option (Right to Buy)	(3)	11/13/2032	Common Stock	16,024	12.5	D
Stock Option (Right to Buy)	(4)	02/28/2034	Common Stock	17,700	5.7	D

Explanation of Responses:

1. These shares include 3,672 restricted stock units ("RSUs") from an original grant of 5,341 RSUs on November 14, 2022. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of the original 5,341 RSUs granted, twenty-five percent (25%) vested on November 14, 2023, and the remaining RSUs vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

2. Twenty-five percent (25%) of the shares subject to the option vested on July 11, 2023, and the remaining shares subject to the option vest in 12 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

3. Twenty-five percent (25%) of the shares subject to the option vested on November 14, 2023, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

4. Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact	05/16/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.